373 related articles for article (PubMed ID: 24234652)
1. LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner.
Ohkawara B; Cabrera-Serrano M; Nakata T; Milone M; Asai N; Ito K; Ito M; Masuda A; Ito Y; Engel AG; Ohno K
Hum Mol Genet; 2014 Apr; 23(7):1856-68. PubMed ID: 24234652
[TBL] [Abstract][Full Text] [Related]
2. Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction.
Maselli RA; Arredondo J; Cagney O; Ng JJ; Anderson JA; Williams C; Gerke BJ; Soliven B; Wollmann RL
Hum Mol Genet; 2010 Jun; 19(12):2370-9. PubMed ID: 20371544
[TBL] [Abstract][Full Text] [Related]
3. LRP4 site-specific variants in the third β-propeller domain causes congenital myasthenic syndrome type 17.
Al Jabry T; Al-Hashmi N; Abdelhadi B; Al-Maawali A
Eur J Med Genet; 2024 Feb; 67():104903. PubMed ID: 38101565
[TBL] [Abstract][Full Text] [Related]
4. New mutation in the β1 propeller domain of LRP4 responsible for congenital myasthenic syndrome associated with Cenani-Lenz syndrome.
Masingue M; Cattaneo O; Wolff N; Buon C; Sternberg D; Euchparmakian M; Boex M; Behin A; Mamchaouhi K; Maisonobe T; Nougues MC; Isapof A; Fontaine B; Messéant J; Eymard B; Strochlic L; Bauché S
Sci Rep; 2023 Aug; 13(1):14054. PubMed ID: 37640745
[TBL] [Abstract][Full Text] [Related]
5. Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling.
Otsuka K; Ito M; Ohkawara B; Masuda A; Kawakami Y; Sahashi K; Nishida H; Mabuchi N; Takano A; Engel AG; Ohno K
Sci Rep; 2015 Sep; 5():13928. PubMed ID: 26355076
[TBL] [Abstract][Full Text] [Related]
6. Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK).
Zhang W; Coldefy AS; Hubbard SR; Burden SJ
J Biol Chem; 2011 Nov; 286(47):40624-30. PubMed ID: 21969364
[TBL] [Abstract][Full Text] [Related]
7. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
Koneczny I; Cossins J; Waters P; Beeson D; Vincent A
PLoS One; 2013; 8(11):e80695. PubMed ID: 24244707
[TBL] [Abstract][Full Text] [Related]
8. Structural insights into the assembly of the agrin/LRP4/MuSK signaling complex.
Xie T; Xu G; Liu Y; Quade B; Lin W; Bai XC
Proc Natl Acad Sci U S A; 2023 Jun; 120(23):e2300453120. PubMed ID: 37252960
[TBL] [Abstract][Full Text] [Related]
9. MuSk function during health and disease.
Herbst R
Neurosci Lett; 2020 Jan; 716():134676. PubMed ID: 31811897
[TBL] [Abstract][Full Text] [Related]
10. The collagen ColQ binds to LRP4 and regulates the activation of the Muscle-Specific Kinase-LRP4 receptor complex by agrin at the neuromuscular junction.
Uyen Dao TM; Barbeau S; Messéant J; Della-Gaspera B; Bouceba T; Semprez F; Legay C; Dobbertin A
J Biol Chem; 2023 Aug; 299(8):104962. PubMed ID: 37356721
[TBL] [Abstract][Full Text] [Related]
11. The MuSK activator agrin has a separate role essential for postnatal maintenance of neuromuscular synapses.
Tezuka T; Inoue A; Hoshi T; Weatherbee SD; Burgess RW; Ueta R; Yamanashi Y
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16556-61. PubMed ID: 25368159
[TBL] [Abstract][Full Text] [Related]
12. Agrin/Lrp4 signal constrains MuSK-dependent neuromuscular synapse development in appendicular muscle.
Walker LJ; Roque RA; Navarro MF; Granato M
Development; 2021 Nov; 148(21):. PubMed ID: 34714331
[TBL] [Abstract][Full Text] [Related]
13. Structural mechanisms of the agrin-LRP4-MuSK signaling pathway in neuromuscular junction differentiation.
Zong Y; Jin R
Cell Mol Life Sci; 2013 Sep; 70(17):3077-88. PubMed ID: 23178848
[TBL] [Abstract][Full Text] [Related]
14. Rapsyn carboxyl terminal domains mediate muscle specific kinase-induced phosphorylation of the muscle acetylcholine receptor.
Lee Y; Rudell J; Yechikhov S; Taylor R; Swope S; Ferns M
Neuroscience; 2008 Jun; 153(4):997-1007. PubMed ID: 18436384
[TBL] [Abstract][Full Text] [Related]
15. Lrp4 is a receptor for Agrin and forms a complex with MuSK.
Kim N; Stiegler AL; Cameron TO; Hallock PT; Gomez AM; Huang JH; Hubbard SR; Dustin ML; Burden SJ
Cell; 2008 Oct; 135(2):334-42. PubMed ID: 18848351
[TBL] [Abstract][Full Text] [Related]
16. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.
Pevzner A; Schoser B; Peters K; Cosma NC; Karakatsani A; Schalke B; Melms A; Kröger S
J Neurol; 2012 Mar; 259(3):427-35. PubMed ID: 21814823
[TBL] [Abstract][Full Text] [Related]
17. Sarcoglycan Alpha Mitigates Neuromuscular Junction Decline in Aged Mice by Stabilizing LRP4.
Zhao K; Shen C; Li L; Wu H; Xing G; Dong Z; Jing H; Chen W; Zhang H; Tan Z; Pan J; Xiong L; Wang H; Cui W; Sun XD; Li S; Huang X; Xiong WC; Mei L
J Neurosci; 2018 Oct; 38(41):8860-8873. PubMed ID: 30171091
[TBL] [Abstract][Full Text] [Related]
18. LRP4 serves as a coreceptor of agrin.
Zhang B; Luo S; Wang Q; Suzuki T; Xiong WC; Mei L
Neuron; 2008 Oct; 60(2):285-97. PubMed ID: 18957220
[TBL] [Abstract][Full Text] [Related]
19. Agrin-LRP4-MuSK signaling as a therapeutic target for myasthenia gravis and other neuromuscular disorders.
Ohno K; Ohkawara B; Ito M
Expert Opin Ther Targets; 2017 Oct; 21(10):949-958. PubMed ID: 28825343
[TBL] [Abstract][Full Text] [Related]
20. APP interacts with LRP4 and agrin to coordinate the development of the neuromuscular junction in mice.
Choi HY; Liu Y; Tennert C; Sugiura Y; Karakatsani A; Kröger S; Johnson EB; Hammer RE; Lin W; Herz J
Elife; 2013 Aug; 2():e00220. PubMed ID: 23986861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
